ALDH1A3
Aldehyde dehydrogenase family 1 member A3
Protein Summary
NAD-dependent aldehyde dehydrogenase that catalyzes the formation of retinoic acid (PubMed:27759097). Has high activity with all-trans retinal, and has much lower in vitro activity with acetaldehyde (PubMed:27759097). Required for the biosynthesis of normal levels of retinoic acid in the embryonic ocular and nasal regions; retinoic acid is required for normal embryonic development of the eye and the nasal region (By similarity). This gene encodes an aldehyde dehydrogenase enzyme that uses retinal as a substrate. Mutations in this gene have been associated with microphthalmia, isolated 8, and expression changes have also been detected in tumor cells. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jun 2014]
- ENST00000329841
- ENSP00000332256
- ENSG00000184254
- ALDH6
- ALDH6
- MCOP8
- RALDH3
- ALDH1A6
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
PubMedID | 0.97 | ||
gene perturbation | 0.95 | ||
molecular function | 0.86 | ||
protein domain | 0.85 | ||
small molecule perturbation | 0.81 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 175.37 (req: < 5)
Gene RIFs: 69 (req: <= 3)
Antibodies: 194 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 175.37 (req: >= 5)
Gene RIFs: 69 (req: > 3)
Antibodies: 194 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 23
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 49
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0